| Issue | Title | |
| Vol 2013, No 6 (2013) | BTG Expands Interventional Medicine Business with Acquisitions of Ekos and Nordion’s Targeted Therapies Division | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 10 (2010) | BTG Strengthens its Speciality Portfolio with Biocompatibles Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 11 (2009) | Burgeoning Obesity Market Attracts Takeda and Amylin | Abstract |
| Taskin Ahmed | ||
| Vol 2022, No 11 (2022) | Busy Start to Q4 in M&A Deal Making | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2005, No 62 (2005) | Byetta (exenatide) | Abstract pdf |
| Business Review Editor | ||
| Vol 2022, No 4 (2022) | Caladrius and Cend Merge to Become Lisata Therapeutics | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2005, No 66 (2005) | Can European VCs and Universities Make Money from New Biotech Spin-Offs? | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 67 (2006) | Cancer Research Technology | Abstract |
| Business Review Editor | ||
| Vol 2007, No 81 (2007) | Cardinal Divests Segment to Blackstone | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 4 (2009) | Cardiome Gets Lifeline with Merck Deal | Abstract |
| Taskin Ahmed | ||
| Vol 2008, No 102 (2008) | Cash-strapped TorreyPines Divests its Alzheimer’s Disease Developments | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2005, No 56 (2005) | CAT and Abbott: A David and Goliath Story | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 33 (2003) | CAT and OGS in US$176 M Merger | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 43 (2004) | CAT Poised to Take Legal Action Against Abbott | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 7 (2009) | Catalyst Biosciences Signs Two Key Deals | Abstract |
| Taskin Ahmed | ||
| Vol 2007, No 79 (2007) | CDC Awards US$11.4 M to Develop Avian Influenza Tests | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 99 (2008) | Cel-Sci’s Multikine Could be Distributed by Teva in Turkey and Israel | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2010, No 7 (2010) | Celgene Acquires Abraxis BioScience to Broaden its Focus in Oncology | Abstract |
| Staff Editor | ||
| Vol 2016, No 12 (2016) | Celgene acquires first asset, marizomib, from partner Triphase Accelerator | Abstract pdf html |
| Natasha Berry | ||
| Vol 2018, No 1 (2018) | Celgene Acquires Impact Biomedicines for up to US$7 B | Abstract pdf html |
| Natasha Piper | ||
| Vol 2013, No 7 (2013) | Celgene Adds Antibody to Multiple Myeloma Pipeline with MorphoSys Deal | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 4 (2010) | Celgene and Agios Form a Global Strategic Collaboration to Target Cancer Metabolism | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 6 (2009) | Celgene and GlobeImmune form a Cancer Partnership | Abstract |
| Taskin Ahmed | ||
| Vol 2018, No 1 (2018) | Celgene Bolsters Pipeline with US$9 B Purchase of Juno Therapeutics | Abstract pdf html |
| Jawala Prasad | ||
| Vol 2018, No 3 (2018) | Celgene Collaborates with Vividion for US$101 M Upfront to Target Tough-to-Drug Proteins | Abstract pdf html |
| Natasha Piper | ||
| Vol 2013, No 4 (2013) | Celgene Endorses Presage Biosciences’ Cancer Drug Analysis Platform with Strategic Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 12 (2009) | Celgene Expands Cancer Portfolio | Abstract |
| Taskin Ahmed | ||
| Vol 2019, No 9 (2019) | Celgene Fortifies Immuno-oncology Presence with Immatics Alliance | Abstract pdf html |
| Michelle Liu | ||
| Vol 2012, No 10 (2012) | Celgene Gains Buyout Option with VentiRx Cancer Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 2 (2012) | Celgene Gains Covalent Drug Pipeline and Platform via Avila Therapeutics Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2014, No 4 (2014) | Celgene Gains Option to Buy Partner Forma Therapeutics via US$600 M Multistage Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 90 (2007) | Celgene Gets Pharmion for US$2.9 B | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 11 (2011) | Celgene Invests US$45 M in Quanticel in Cancer Collaboration with Buyout Option | Abstract |
| Heather Cartwright | ||
| Vol 2015, No 8 (2015) | Celgene Looks to Build Critical Mass in Inflammation and Immunology via US$7.2 B Receptos Acquisition | Abstract html |
| Heather Cartwright & Smita Mishra | ||
| Vol 2013, No 4 (2013) | Celgene Partners with Bluebird Bio to Advance CAR T-Cell Cancer Therapies | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 8 (2013) | Celgene Pays US$100 M for Option to Buy Acetylon and Partners with Array BioPharma | Abstract |
| Heather Cartwright | ||
| Vol 2014, No 5 (2014) | Celgene Pays US$710 M Upfront to License Nogra Pharma’s Phase III-Ready GED-0301 | Abstract |
| Heather Cartwright | ||
| Vol 2015, No 7 (2015) | Celgene Raises the Bar in Immuno-Oncology with US$1 B Bet on JunoTherapeutics | Abstract |
| Heather Cartwright & Rohit Khera | ||
| Vol 2019, No 8 (2019) | Celgene Restructures Jounce Alliance Amid BMS Acquisition | Abstract html pdf |
| Michelle Liu | ||
| Vol 2013, No 1 (2013) | Celgene Signs US$500 M Next-Generation Antibody Deal with Sutro Biopharma | Abstract |
| Heather Cartwright | ||
| Vol 2016, No 6 (2016) | Celgene Spreads its Bets in Immuno-Oncology via New Deal with Agios | Abstract pdf html |
| Natasha Berry & Heather Cartwright | ||
| Vol 2017, No 7 (2017) | Celgene Strengthens Immuno-oncology Franchise with Beigene’s BGB-A317 | Abstract pdf html |
| Jasmine Kalsi | ||
| Vol 2013, No 12 (2013) | Celgene Targets Cancer Stem Cells with US$3.3 B OncoMed Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2016, No 8 (2016) | Celgene Welcomes Jounce to its Immuno-Oncology Collaborators List with US$2.56 B Deal | Abstract pdf html |
| Jawala Prasad & Heather Cartwright | ||
| Vol 2011, No 3 (2011) | Cell Therapeutics Expands its Late-Stage Oncology Pipeline with Chroma Therapeutics’ Tosedostat | Abstract |
| Heather Cartwright | ||
| Vol 2002, No 31 (2002) | Cell Therapeutics Researches Oncology Targets with Hope Heart Institute | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 70 (2006) | Celliance and Novo Nordisk Extend Insulin Distribution Alliance | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 45 (2004) | Celltech and Biogen Idec Form Autoimmune Disease Collaboration | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 43 (2004) | Celltech Regains Drug Rights from Pfizer | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 36 (2003) | Celltech, Oxford GlycoSciences and the Bidding War That Never Was | Abstract |
| Business Review Editor | ||
| Vol 2008, No 100 (2008) | Cellzome’s Billion Dollar Deal with GSK | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2002, No 31 (2002) | CeNeS Licenses MS Treatment to Acorda | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 26 (2002) | Centocor and Neuronyx Enter Cardiovascular Stem Cell Collaboration | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 38 (2003) | Centocor Collaborates with Biolex for Therapeutic Protein Production | Abstract |
| Business Review Editor | ||
| Vol 2005, No 56 (2005) | Centocor Partners Neurochem to Gain Access to Amyloidosis Drug | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 61 (2005) | Cephalon Acquires Cancer Drug Trisenox® from Cell Therapeutics | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 2 (2010) | Cephalon Acquires Generic Drug maker Mepha | Abstract |
| Taskin Ahmed | ||
| Vol 2011, No 4 (2011) | Cephalon Agrees to Buy Gemin X Pharmaceuticals for up to US$525 M | Abstract |
| Heather Cartwright | ||
| Vol 2003, No 34 (2003) | Cephalon Announces Takeover Bid for SIRTeX Medical | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 102 (2008) | Cephalon Signs Option Agreement for ImmuPharma’s First-in-class Lupus Drug | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2006, No 67 (2006) | Cephalon to Expand European Operations | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 4 (2009) | Cephalon’s Deal to Acquire Arana Therapeutics | Abstract |
| Taskin Ahmed | ||
| Vol 2006, No 74 (2006) | Ceplene (histamine dihydrochloride) | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 84 (2007) | Cervarix | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 73 (2006) | Challenging the Biotech Business Model | Abstract html |
| Fintan Walton | ||
| Vol 2009, No 4 (2009) | Challenging Times in Deal Making : Highlights from BioTrinity 2009 | Abstract |
| Taskin Ahmed | ||
| Vol 2006, No 72 (2006) | Chelsea Augments its Pipeline | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 4 (2009) | Chicken Soup | Abstract jpg |
| Clive Goddard | ||
| Vol 2004, No 54 (2004) | Chiesi Group SpA | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 57 (2005) | Chiesi Licenses Second Drug to GB Therapeutics | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 46 (2004) | Chiron and Xoma to Develop Anticancer Antibodies | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 29 (2002) | Chiron to use Serenex’s Proteome Mining™ Technology | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 37 (2003) | Chiron’s Acquisition of Powderject | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 86 (2007) | Chroma Therapeutics Ltd | Abstract |
| Business Review Editor | ||
| Vol 2004, No 50 (2004) | Chromos to Acquire CellExSys and its T-Cell Technology | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 34 (2003) | Chugai Pharmaceuticals Co., Ltd | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 43 (2004) | CIMA Labs Licenses Fast-Dissolving Fentanyl to Taiho | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 77 (2006) | Cimzia (certolizumab) | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 11 (2012) | Cinven Makes Second Speciality Pharma Acquisition of 2012 | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 12 (2009) | Clavis and Clovis Collaborate on Anticancer Drug CP-4126 | Abstract |
| Taskin Ahmed | ||
| Vol 2008, No 93 (2008) | Clinical Development Attrition Rates | Abstract |
| John Janes | ||
| Vol 2006, No 67 (2006) | Cloning | Details jpg |
| Business Review Editor | ||
| Vol 2013, No 12 (2013) | Clovis Expands Portfolio of Targeted Cancer Drugs with EOS Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 5 (2010) | Clovis Oncology and Avila Therapeutics to Collaborate on Novel Lung Cancer Drug | Abstract |
| Debbie Tranter | ||
| Vol 2004, No 51 (2004) | Codexis and Pfizer Collaborate on Pharmaceutical Life Cycle Management | Abstract pdf |
| Business Review Editor | ||
| Vol 2019, No 1 (2019) | Codiak Biosciences’ Exosome Therapeutics Attracts Jazz Pharmaceuticals | Abstract pdf html |
| Michelle Liu | ||
| Vol 2023, No 6 (2023) | Coherus Biosciences to Buy Surface Oncology for US$65 M | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2021, No 2 (2021) | Coherus Catapults into Immuno-oncology Field with US$1.8 B Junshi Alliance | Abstract pdf html |
| Michelle Liu | ||
| Vol 2002, No 24 (2002) | Cohesion and Zycos in PEG drug delivery collaboration | Abstract pdf |
| Business Review Editor | ||
| Vol 2024, No 8 (2024) | Collegium to Acquire Ironshore Therapeutics for US$525 M | Abstract pdf html |
| Ayush Saxena | ||
| Vol 2005, No 65 (2005) | CombinatoRx and Angiotech Collaborate in Systems Biology | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 8 (2009) | CombinatoRx and Clinical Data Collaborate on Adenosine Agonist for Cancer | Abstract |
| Taskin Ahmed | ||
| Vol 2006, No 69 (2006) | CombinatoRx and Fovea in Alliance to Treat Ophthalmic Disease | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 7 (2009) | CombinatoRx and Neuromed Sign Merger Agreement | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 5 (2009) | CombinatoRx's Oncology Collaboration with Novartis | Abstract |
| Taskin Ahmed | ||
| Vol 2016, No 12 (2016) | Committed to Amyloid Research, Lilly Expands its Collaboration with AstraZeneca | Abstract pdf html |
| Natasha Berry & Jawala Prasad | ||
| Vol 2007, No 87 (2007) | Communicating Health | Abstract html |
| Fintan Walton | ||
| Vol 2005, No 66 (2005) | Communication, Trust and the Deal | Abstract html |
| Fintan Walton | ||
| Vol 2005, No 59 (2005) | Competition Forces Organon and J&J to Terminate Co-Promotion of Risperdal® | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 94 (2008) | Competition Law and Intellectual Property Strategy in the Pharmaceuticals Sector: a review of a recently published report | Abstract pdf |
| Business Review Editor | ||
| 801 - 900 of 2581 Items | << < 4 5 6 7 8 9 10 11 12 13 > >> | |